Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 14/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2246265 | 0.94 | CALCRL (0.63) | CALCRLCYP3A4PARP1 | |
| SCHEMBL3780293 | 0.89 | CALCRL (0.57) | CALCRLTRPV1CYP3A4 | |
| SCHEMBL2209945 | 0.87 | CALCRL (0.61) | CALCRLCYP3A4PARP1 | |
| SCHEMBL2211139 | 0.86 | CALCRL (0.54) | CALCRLCYP3A4PARP1 | |
| SCHEMBL12511951 | 0.81 | CALCRL (0.56) | CALCRLCYP3A4 | |
| SCHEMBL14385938 | 0.78 | CALCRL (0.59) | CALCRLTRPV1CYP3A4 | |
| SCHEMBL2214009 | 0.78 | CALCRL (0.43) | CALCRLCA1CA2ACHEPARP1 | |
| SCHEMBL2213969 | 0.77 | CALCRL (0.61) | CALCRLTRPV1PARP1 | |
| SCHEMBL2213111 | 0.77 | CALCRL (0.55) | CALCRLTRPV1PARP1 | |
| SCHEMBL13804327 | 0.75 | CALCRL (0.52) | CALCRLPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796260-B2 | Imidazobenzazepine CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796260-B2 | Imidazobenzazepine CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20100324023-A1 | IMIDAZOBENZAZEPINE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324023-A1 | IMIDAZOBENZAZEPINE CGRP RECEPTOR ANTAGONISTS | BDKRB1, CCKBR, CALCRL | CALCRL 3/4885CA1 2661/4885CA2 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.